- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00435097
Computer Assisted Early Detection of Liver Metastases From fMRI Maps
Study Overview
Status
Conditions
Detailed Description
In this research, we propose to develop methods and protocols for imaging-based, non-invasive early detection and diagnosis of colon cancer metastases. Colon cancer is the third most common cancer worldwide. While it is amenable to surgery if detected early, advanced carcinomas are usually lethal, with liver metastases being the most common cause of death. Early and accurate detection of these lesions is recognized as having the potential of improving survival rates and reducing treatment morbidity. Current diagnostic imaging offers improved discrimination and sensitivity that can be used for earlier detection of smaller lesions conducive to curative therapy.
In previous research, we demonstrated the feasibility of fMRI based on hypercapnia and hyperoxia for monitoring changes in liver perfusion and hemodynamics without contrast agent administration. The isolation and analysis of areas with significant hemodynamical changes in images acquired at early phase of tumor development has proven to be a difficult, time consuming, and potentially unreliable task. Our goal is thus two-fold: 1. use image processing and machine learning tools on a training set of hemodynamical maps obtained from well validated tumors to automate the process and improve its discrimination and sensitivity characteristics, and; 2. implement our method in patients with colorectal liver metastases. The method can help general radiologists with no image processing training to highlight undetectable tumors from background noise and increase diagnosis specificity and sensitivity.
Study Type
Contacts and Locations
Study Contact
- Name: Ayala Hubert, MD
- Email: ayalah@hadassah.org.il
Study Contact Backup
- Name: Hadas Lemburg, PhD
- Phone Number: 00 972 2 6777572
- Email: lhadas@hadassah.org.il
Study Locations
-
-
-
Jerusalem, Israel, 91120
- Hadassah Medical Organization
-
Principal Investigator:
- Ayala Hubert, MD
-
Principal Investigator:
- Rinat Abramovitch, PhD
-
Jerusalem, Israel, 96000
- Hebrew University
-
Principal Investigator:
- Leo Joskowicz, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Control group of healthy volunteers
- Study group: Patients with colon cancer stage III or IV with high suspicion of liver metastases: raising CEA, suspected lesion in the liver by CT or PET.
Exclusion Criteria:
- Contraindication to perform MRI.
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Abramovitch Rinat, PhD, Hadassah Medical Organization
- Principal Investigator: Joskowicz Leo, PhD, Hebrew University, Jerusalem
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- colmri-HMO-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
Symphogen A/STerminatedCarcinoma | Metastatic Colorectal Cancer | Colorectal Cancer MetastaticUnited States, Spain, Germany, Italy